RecruitingPhase 1NCT06928246

The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

Pilot Study on Cellular and Molecular Impact of Neuroimmune Interactions in Atopic Dermatitis


Sponsor

Daniel Kaplan

Enrollment

8 participants

Start Date

Jul 17, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to understand cellular and molecular interactions in the skin of participants with mild-to-moderate AD, and how botulinum toxin alters these interactions.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Onabotulinum Toxin Type A - Phase 1b and a drug called Onabotulinum Toxin Type A - Phase 2 for people with atopic dermatitis (ad). The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOnabotulinum Toxin Type A - Phase 1b

The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 50 units per patient.

DRUGOnabotulinum Toxin Type A - Phase 2

The lesions receiving Botulinum toxin will get five 0.1 mL intradermal injections of 5 units of Botulinum toxin which equates to 25 units per lesion and 75 units per patient.


Locations(2)

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

UPMC Department of Dermatology

Pittsburgh, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06928246


Related Trials